NASDAQ:BPMC Blueprint Medicines - BPMC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. $47.78 +0.03 (+0.06%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$47.01▼$48.0050-Day Range$41.92▼$50.1952-Week Range$40.78▼$85.67Volume282,590 shsAverage Volume461,733 shsMarket Capitalization$2.86 billionP/E RatioN/ADividend YieldN/APrice Target$79.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Blueprint Medicines MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside63.5% Upside$78.11 Price TargetShort InterestBearish8.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 15 Articles This WeekInsider TradingSelling Shares$1.03 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($9.38) to ($9.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector601st out of 1,055 stocksPharmaceutical Preparations Industry304th out of 519 stocks 4.3 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 8 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.11, Blueprint Medicines has a forecasted upside of 63.5% from its current price of $47.78.Amount of Analyst CoverageBlueprint Medicines has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.23% of the float of Blueprint Medicines has been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Blueprint Medicines has recently increased by 3.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 3.0 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Blueprint Medicines this week, compared to 3 articles on an average week.Search Interest2 people have searched for BPMC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold 2,020.62% more of their company's stock than they have bought. Specifically, they have bought $48,378.00 in company stock and sold $1,025,913.00 in company stock.Percentage Held by InsidersOnly 3.42% of the stock of Blueprint Medicines is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to decrease in the coming year, from ($9.38) to ($9.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Blueprint Medicines (NASDAQ:BPMC) StockBlueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.Read More Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Price Target Cut to $44.00January 24, 2023 | msn.comBlueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority TagJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 23, 2023 | marketwatch.comBlueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic Mastocytosis >BPMCJanuary 23, 2023 | markets.businessinsider.comBlueprint Medicines: FDA Grants Priority Review For Supplemental New Drug Application For AYVAKITJanuary 23, 2023 | finance.yahoo.comBlueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic MastocytosisJanuary 22, 2023 | markets.businessinsider.comBarclays Keeps Their Hold Rating on Blueprint Medicines (BPMC)January 22, 2023 | reuters.comBPMC.O - | Stock Price & Latest News | ReutersJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 13, 2023 | finance.yahoo.comADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?January 9, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Blueprint Medicines (BPMC)January 6, 2023 | finance.yahoo.comBlueprint Medicines Appoints John Tsai, M.D. to its Board of DirectorsJanuary 5, 2023 | finance.yahoo.comBlueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at ScaleDecember 31, 2022 | finance.yahoo.comShareholders in Blueprint Medicines (NASDAQ:BPMC) are in the red if they invested a year agoDecember 14, 2022 | msn.comBlueprint initiated Buy at Needham citing sales prospects for cancer therapyDecember 14, 2022 | seekingalpha.comBlueprint Medicines: A Slow But Steady Blueprint For SuccessDecember 12, 2022 | seekingalpha.comBlueprint reports long term data for Ayvakit; elenestinib shows promise in phase 1 trialDecember 11, 2022 | finance.yahoo.comBlueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic MastocytosisDecember 2, 2022 | finance.yahoo.comAcadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?November 23, 2022 | finance.yahoo.comBlueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SMNovember 22, 2022 | finance.yahoo.comBlueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic MastocytosisNovember 8, 2022 | finance.yahoo.comBlueprint Medicines Third Quarter 2022 Earnings: Beats ExpectationsNovember 7, 2022 | msn.comBlueprint Medicines's Return On Capital Employed OverviewNovember 6, 2022 | finance.yahoo.comWhat Does The Future Hold For Blueprint Medicines Corporation (NASDAQ:BPMC)? These Analysts Have Been Cutting Their EstimatesNovember 4, 2022 | seekingalpha.comBlueprint cut to Perform at Baird on slow uptake for cancer therapyNovember 4, 2022 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)November 3, 2022 | finance.yahoo.comBlueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual MeetingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Company Calendar Last Earnings11/01/2022Today1/27/2023Next Earnings (Estimated)2/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees495Year FoundedN/APrice Target and Rating Average Stock Price Forecast$78.11 High Stock Price Forecast$115.00 Low Stock Price Forecast$41.00 Forecasted Upside/Downside+66.4%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($12.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-644,090,000.00 Net Margins-263.54% Pretax Margin-261.03% Return on Equity-56.45% Return on Assets-36.25% Debt Debt-to-Equity Ratio0.19 Current Ratio6.99 Quick Ratio6.79 Sales & Book Value Annual Sales$180.08 million Price / Sales15.87 Cash FlowN/A Price / Cash FlowN/A Book Value$16.50 per share Price / Book2.90Miscellaneous Outstanding Shares59,831,000Free Float57,785,000Market Cap$2.86 billion OptionableOptionable Beta0.64 Key ExecutivesKathryn HavilandPresident, Chief Executive Officer & DirectorChristina RossiChief Operating OfficerMichael LandsittelChief Financial OfficerChristopher K. MurraySenior Vice President-Technical OperationsBecker HewesChief Medical OfficerKey CompetitorsMirati TherapeuticsNASDAQ:MRTXAmylyx PharmaceuticalsNASDAQ:AMLXRevance TherapeuticsNASDAQ:RVNCProthenaNASDAQ:PRTAInsmedNASDAQ:INSMView All CompetitorsInsiders & InstitutionsComerica BankBought 6,386 shares on 1/26/2023Ownership: 0.132%Strs OhioSold 4,000 shares on 1/26/2023Ownership: 0.003%Moody Aldrich Partners LLCSold 697 shares on 1/24/2023Ownership: 0.029%Oak Ridge Investments LLCSold 862 shares on 1/24/2023Ownership: 0.025%Harbor Investment Advisory LLCSold 2,373 shares on 1/24/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions BPMC Stock - Frequently Asked Questions Should I buy or sell Blueprint Medicines stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 sell rating, 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPMC shares. View BPMC analyst ratings or view top-rated stocks. What is Blueprint Medicines' stock price forecast for 2023? 16 brokers have issued 12-month price targets for Blueprint Medicines' stock. Their BPMC share price forecasts range from $41.00 to $115.00. On average, they anticipate the company's stock price to reach $78.11 in the next twelve months. This suggests a possible upside of 64.6% from the stock's current price. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts. How have BPMC shares performed in 2023? Blueprint Medicines' stock was trading at $43.81 at the beginning of 2023. Since then, BPMC stock has increased by 8.3% and is now trading at $47.46. View the best growth stocks for 2023 here. When is Blueprint Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023. View our BPMC earnings forecast. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) announced its quarterly earnings data on Tuesday, November, 1st. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.51) by $0.28. The biotechnology company had revenue of $65.98 million for the quarter, compared to analysts' expectations of $43.49 million. Blueprint Medicines had a negative net margin of 263.54% and a negative trailing twelve-month return on equity of 56.45%. What guidance has Blueprint Medicines issued on next quarter's earnings? Blueprint Medicines issued an update on its FY 2022 earnings guidance on Thursday, January, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.00 million-$200.00 million, compared to the consensus revenue estimate of $199.69 million. What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR). When did Blueprint Medicines IPO? (BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Blueprint Medicines' stock symbol? Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC." Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by many different retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.21%), Comerica Bank (0.13%), Assenagon Asset Management S.A. (0.06%), Moody Aldrich Partners LLC (0.03%), Oak Ridge Investments LLC (0.03%) and Strs Ohio (0.00%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Marion Dorsch, Mark Alan Goldberg, Nicholas Lydon, Percy H Carter and Tracey L Mccain. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Blueprint Medicines' stock price today? One share of BPMC stock can currently be purchased for approximately $47.46. How much money does Blueprint Medicines make? Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $2.84 billion and generates $180.08 million in revenue each year. The biotechnology company earns $-644,090,000.00 in net income (profit) each year or ($12.10) on an earnings per share basis. How many employees does Blueprint Medicines have? The company employs 495 workers across the globe. How can I contact Blueprint Medicines? Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com. This page (NASDAQ:BPMC) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.